US Patent 8,809,307 Landscape: Halobetasol Propionate Topical Compositions Using Dicarboxylic Acid Esters
What is the patent’s core claim scope (composition + solubilization metric)?
US 8,809,307 claims topical skin formulations that combine:
1) Halobetasol propionate at 0.04% or less, and
2) A liquid oil component comprising one or more dicarboxylic acid esters chosen from:
- Diethyl sebacate
- Diisopropyl adipate
- Dibutyl sebacate
3) A solubilization requirement at 22°C: at least 25% of the halobetasol propionate is solubilized in the liquid oil component at 22°C.
This is a narrow, performance-defined formulation claim set. The distinguishing feature is not just the ingredients, but the specific solubilized fraction at room temperature and the oil quantity relative to complete solubilization.
Claim 1 establishes the anchor limitations
Claim 1 requires all of the following:
- Topical composition for application to skin
- Halobetasol propionate concentration ≤ 0.04%
- Liquid oil component includes dicarboxylic acid ester(s) selected from:
- diethyl sebacate, diisopropyl adipate, dibutyl sebacate
- Solubilization threshold: ≥ 25% of halobetasol propionate solubilized in the liquid oil component at 22°C
Practical impact of Claim 1
Any product or formulation design that:
- swaps the oil phase away from those specific dicarboxylic acid esters, or
- increases halobetasol above 0.04%, or
- cannot demonstrate the ≥25% solubilized fraction at 22°C
falls outside Claim 1’s literal scope.
How do dependent claims tighten potency and solubilization conditions?
The dependent claims add three main tightening axes:
1) Lower halobetasol concentration ceilings
2) Oil-to-drug ratio bounds tied to “complete solubilization” at 22°C ± 2°C
3) Higher solubilized fraction inside the oil
Potency ceilings
- Claim 2: halobetasol ≤ 0.025%
- Claim 3: halobetasol ≤ 0.01%
These define a graduated narrowing. Products in the 0.01% to 0.025% band can implicate higher-tier dependents; products above 0.025% can still fall into Claim 1 scope depending on the solubilization performance.
Oil-to-drug ratio (relative to “complete solubilization” at 22°C ± 2°C)
- Claim 4: oil concentration is sufficient to dissolve the amount of halobetasol at 22°C ± 2°C
- Claim 5: oil concentration is 1.5 to 3 times the amount required for complete solubilization at 22°C ± 2°C
- Claim 6: oil concentration is 1.75 to 2.75 times the amount required for complete solubilization at 22°C ± 2°C
These claims are unusual because they require quantitative formulation ratios expressed relative to an experimentally defined baseline (“amount required to completely solubilize”).
Solubilized fraction escalation (within the oil phase)
- Claim 7: ester concentration in oil is ≥ 30% of liquid oil component concentration (internal composition constraint)
- Claim 8: ≥ 50%
- Claim 9: ≥ 70%
- Claim 10: ≥ 90%
- Claim 11: 100% (meaning the liquid oil component is entirely the dicarboxylic ester(s) with no other oil diluents)
A second solubilization concept exists in Claim 13 (lower halobetasol case), which states solubilization directly as a fraction of halobetasol at room temperature. Claims 7–11 instead tune ester fraction within the oil, not the halobetasol solubilized fraction.
What specific embodiments are singled out?
Specific ester identity
- Claim 12: dicarboxylic acid ester is diethyl sebacate
Specific combined embodiment
- Claim 13: halobetasol ≤ 0.025%, liquid oil comprises diethyl sebacate, and ≥ 50% of halobetasol is solubilized at room temperature
- Claim 14: ties to the 1.5 to 3× oil ratio window for complete solubilization at 22°C ± 2°C
Liquid oil co-ingredients (mineral oil and additional esters)
- Claim 19: liquid oil further comprises light mineral oil
- Claim 20: liquid oil comprises diethyl sebacate and light mineral oil
- Claim 21: liquid oil comprises diethyl sebacate and isopropyl myristate
These broaden the composition space by adding other non-specified oils while keeping the dicarboxylic ester(s) as the required core.
How do method claims map to the composition claims?
The method claims are “provide composition of claim X and apply effective amount” constructs, so infringement turns on whether the supplied product composition meets the corresponding composition claim limitations.
- Claim 15: method using composition of claim 1
- Claim 16: method using composition of claim 4
- Claim 17: method using composition of claim 13
These covers both clinical/therapeutic use and the composition profile, but they do not add separate mechanistic constraints beyond “amenable to treatment with a topical corticosteroid” and “effective in ameliorating signs or symptoms.”
What is the residual claim ambiguity inside the provided text?
One entry is internally inconsistent in labeling:
- Claim 18: “The pharmaceutical composition of claim wherein…” (no explicit dependency number shown)
- Claim 22 appears as a composition claim but repeats the general Claim 1 structure plus the explicit oil ratio window.
Because the claim text provided is partially malformed, only the clearly stated limitations can be treated as reliable for scope. The landscape conclusions below rely only on limitations that are explicitly present.
How does the claim structure define a “design space” for competitors?
A practical way to view US 8,809,307 is as a three-factor gate:
Gate A: Actives and concentration
- Halobetasol propionate ≤ 0.04%
- If the product is formulated above that, it avoids Claim 1 and its dependents that retain the same ceiling.
Gate B: Oil identity
- Liquid oil includes dicarboxylic acid ester(s) in the set:
- diethyl sebacate
- diisopropyl adipate
- dibutyl sebacate
If a competitor uses a different solvent or emollient system without these specific esters as the dicarboxylic acid ester component, the claims are likely avoided.
Gate C: Performance at 22°C
- Claim 1 threshold: at least 25% of halobetasol is solubilized in the liquid oil component at 22°C
- Dependent thresholds further restrict:
- in certain embodiments (e.g., Claim 13), ≥ 50% solubilization is required at room temperature
- and oil amount must be 1.5 to 3× (or 1.75 to 2.75×) of the complete-solubilization requirement at 22°C ± 2°C
This means many otherwise plausible topical halobetasol formulations can still fall outside the patent if the solubilization behavior differs.
Claim-by-claim “scope ladder” summary
The following table consolidates the provided limitations into an at-a-glance dependency ladder.
| Claim tier |
What it adds vs. Claim 1 base |
Key numeric limits |
| Claim 1 |
Anchor composition and ester set + solubilization at 22°C |
Halobetasol ≤ 0.04%; ester(s): diethyl sebacate/diisopropyl adipate/dibutyl sebacate; solubilized ≥ 25% at 22°C |
| Claim 2 |
Lower halobetasol |
≤ 0.025% |
| Claim 3 |
Further lower halobetasol |
≤ 0.01% |
| Claim 4 |
Oil sufficiency |
Oil dissolves halobetasol at 22°C ± 2°C |
| Claim 5 |
Broader oil ratio window |
oil = 1.5 to 3× complete solubilization amount at 22°C ± 2°C |
| Claim 6 |
Tighter oil ratio window |
oil = 1.75 to 2.75× complete solubilization amount at 22°C ± 2°C |
| Claims 7-11 |
Ester fraction in oil |
ester fraction in liquid oil: ≥30%, ≥50%, ≥70%, ≥90%, 100% |
| Claim 12 |
Ester identity |
diethyl sebacate |
| Claim 13 |
Lower halobetasol + higher solubilization fraction |
halobetasol ≤0.025%; oil includes diethyl sebacate; halobetasol solubilized ≥50% at room temperature |
| Claim 14 |
Oil ratio tied to Claim 13 |
oil = 1.5 to 3× complete solubilization amount at 22°C ± 2°C |
| Claim 19-21 |
Allow additional oils |
light mineral oil; optionally diethyl sebacate + light mineral oil; optionally diethyl sebacate + isopropyl myristate |
| Claim 22 |
Restated composition with key oil ratio |
repeats Claim 1 plus oil ratio (1.5 to 3×) |
| Claims 23-27 |
Restated ester fraction in oil |
≥30% / ≥50% / ≥70% / ≥90% / 100% ester fraction in oil |
| Claim 28 |
Restates mineral oil add-on |
liquid oil further comprises light mineral oil |
| Claims 15-17 |
Use methods tied to composition claims |
provide composition of claim 1/4/13 and apply effective amount |
Competitive patent landscape read-through (what likely matters in freedom-to-operate)
1) The claim is ingredient-paired with a performance requirement
Many topical corticosteroid patents claim specific solvents, penetration enhancers, emulsions, or vehicles. US 8,809,307 adds a measurable condition:
- “solubilized” fraction at 22°C
This increases the importance of formulation characterization evidence.
2) Design-around focuses on one of three levers
For a competitor trying to avoid the claim set, the most direct levers are:
- Replace the oil phase so the liquid oil component does not include the claimed dicarboxylic acid esters as specified.
- Move halobetasol propionate above 0.04% (if clinically viable and separately protected).
- Alter the formulation so the solubilized fraction at 22°C does not reach the claimed thresholds.
- Avoid the specific oil amount windows (1.5 to 3×; 1.75 to 2.75×) relative to “complete solubilization” at 22°C ± 2°C.
3) If the product uses diethyl sebacate-based liquid oil with low halobetasol, the risk concentrates
The narrowest embodiments are built around:
- diethyl sebacate
- halobetasol ≤ 0.025%
- ≥50% solubilization at room temperature (Claim 13)
- optional co-solvent additions (light mineral oil; isopropyl myristate)
So the highest-risk competitor formulations are those that intentionally target increased solubility of halobetasol in a diethyl sebacate oil phase at ambient temperatures.
Scope triggers for enforcement scenarios
US 8,809,307 would typically be asserted where:
- The accused product is a topical halobetasol formulation with ≤0.04% halobetasol, and
- Its vehicle contains diethyl sebacate and/or diisopropyl adipate and/or dibutyl sebacate as the dicarboxylic ester component, and
- Testing shows that a substantial fraction of halobetasol is solubilized in the oil at 22°C.
Because the claims recite concentration ceilings and solubilization fractions, infringement can hinge on lab characterization:
- quantifying what fraction is solubilized in the liquid oil phase at 22°C (and at room temperature for Claim 13),
- verifying the oil-to-drug ratio relative to the “complete solubilization” baseline at 22°C ± 2°C,
- verifying ester fraction within the oil if dependents 7–11 or 23–27 are asserted.
Key Takeaways
- US 8,809,307 covers topical halobetasol propionate formulations using specific dicarboxylic acid esters (diethyl sebacate, diisopropyl adipate, dibutyl sebacate) with a required solubilization performance at 22°C.
- Claim 1 is the anchor: halobetasol ≤0.04% and ≥25% of halobetasol is solubilized in the oil phase at 22°C.
- The risk of capture increases if a product also fits the dependent tightening constraints: lower halobetasol (≤0.025%, ≤0.01%), specific oil ratio windows tied to “complete solubilization” at 22°C ± 2°C, and high ester fractions in the oil.
- The enforcement trigger is not only ingredient choice but the measured solubilized fraction and ratio-defined formulation behavior at ambient temperature.
FAQs
1) What is the minimum halobetasol solubilized fraction required by the broadest composition claim?
At least 25% of halobetasol propionate must be solubilized in the liquid oil component at 22°C (Claim 1).
2) Which dicarboxylic acid esters are explicitly covered?
Diethyl sebacate, diisopropyl adipate, and dibutyl sebacate are the specified ester options.
3) How does the patent control the amount of oil used?
It requires oil levels tied to “complete solubilization” at 22°C ± 2°C, with windows such as 1.5 to 3× (Claim 5) and 1.75 to 2.75× (Claim 6).
4) Does the patent cover vehicles that include light mineral oil?
Yes. Dependent claims include embodiments where the liquid oil component further comprises light mineral oil (Claims 19, 20, and 28).
5) Are the method claims broader than the composition claims?
They are tethered to specific composition claims (Claims 15–17). If the supplied formulation does not meet the corresponding composition limitations, method coverage does not attach.
References
[1] United States Patent 8,809,307, “Pharmaceutical composition for topical application,” claim text as provided by user.
